Status:

COMPLETED

A Phase 1-2 Study of PRT-201 Administered in Chronic Kidney Disease (CKD) Patients

Lead Sponsor:

Proteon Therapeutics

Conditions:

Chronic Kidney Disease

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

PRT-201 is a protein that causes long lasting dilation of blood vessels when applied to the outside surface of the blood vessel. The purpose of this study is to determine if PRT-201, when applied to a...

Eligibility Criteria

Inclusion

  • Age of at least 18 years.
  • Chronic kidney disease with anticipated start of hemodialysis within six months or current hemodialysis dependence.
  • Planned creation of a new AVF.

Exclusion

  • Patients for whom this is the only potential site for an AVF.
  • By physical examination, absence of radial or ulnar artery flow or non-patent palmer arch.
  • Treatment with any investigational agent within the previous 30 days or investigational antibody therapy within 90 days of signing informed consent.
  • Pregnancy, lactation or plans to become pregnant during the course of the study.

Key Trial Info

Start Date :

November 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2011

Estimated Enrollment :

66 Patients enrolled

Trial Details

Trial ID

NCT00679991

Start Date

November 1 2008

End Date

July 1 2011

Last Update

April 30 2015

Active Locations (11)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (11 locations)

1

Clarian Health Partners/Indiana University/Purdue University

Indianapolis, Indiana, United States, 46202

2

University of Iowa Hospitals and Clinics

Iowa City, Iowa, United States, 52242

3

Maine Medical Center

Portland, Maine, United States, 04102

4

Brigham and Women's Hospital

Boston, Massachusetts, United States, 02115

A Phase 1-2 Study of PRT-201 Administered in Chronic Kidney Disease (CKD) Patients | DecenTrialz